Aging and Prostatic Hyperplasia in Transgenic Mice

转基因小鼠的衰老和前列腺增生

基本信息

项目摘要

DESCRIPTION (provided by applicant): Age-associated benign prostatic hyperplasia (BPH) is a major health problem of elderly men. The molecular etiology of BPH is complex and not clearly understood. Chronic influence of multiple regulatory factors including androgen and peptide growth factors are suspected to contribute to pro static cell proliferation and pathogenesis. The species-specific nature of BPH and the lack of an appropriate mouse model have impeded progress in the delineation of the causal factors for the development of BPH and testing of potential intervention strategies. It is our hypothesis that prostate-specific overexpression of the androgen receptor (AR) and insulinlike growth factor-1 (IGF- 1) in transgenic mice would cause increased prostatic cell proliferation and would give rise to a pathological condition similar to human BPH. The first specific aim of this proposal is to generate transgenic mice overexpressing AR in the prostate targeted by a ten kilobase pair long homologous mouse probasin gene promoter and to characterize the age-and androgen-dependent changes in the prostatic morphology, cellular composition and gene expression profiles. Region (proximal, intermediate and distal)- and lobe-specific histopathologic changes during aging will be correlated with gene expression profiles determined by micro array analysis. In the second specific aim, we will elucidate the interacting role of AR and IGF-1 in promoting aberrant cell proliferation and gene expression through comparative analysis of monotransgenic mice with individual prostatic overexpression of AR and IGF- 1 and bitransgenic mice with simultaneous overexpression of both AR and IGF- 1 in the prostate. Our preliminary results support the feasibility of the proposed experiments and successful completion of this study is expected to provide important new insights into the cellular and molecular pathways that lead to the development of the prostatic hyperplasia under the influence of physiological stimuli. Additionally, the transgemc model and molecular markers generated through these investigations will be beneficial for future studies concerning the development of effective intervention strategies and progression/remission of the disease process.
描述(由申请人提供):与年龄相关的良性前列腺

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BANDANA CHATTERJEE其他文献

BANDANA CHATTERJEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BANDANA CHATTERJEE', 18)}}的其他基金

Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
维生素 D3、干扰雄激素信号和抑制前列腺癌
  • 批准号:
    8391126
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
维生素 D3、干扰雄激素信号和抑制前列腺癌
  • 批准号:
    7789641
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Regulation of Intratumor Androgen/Androgen Receptor signaling in Prostrate Cancer
前列腺癌瘤内雄激素/雄激素受体信号传导的调节
  • 批准号:
    8635707
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
维生素 D3、干扰雄激素信号和抑制前列腺癌
  • 批准号:
    7687861
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
维生素 D3、干扰雄激素信号和抑制前列腺癌
  • 批准号:
    8195918
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Regulation of Intratumor Androgen/Androgen Receptor signaling in Prostrate Cancer
前列腺癌瘤内雄激素/雄激素受体信号传导的调节
  • 批准号:
    8811322
  • 财政年份:
    2009
  • 资助金额:
    $ 25.29万
  • 项目类别:
Aging and Prostatic Hyperplasia in Transgenic Mice
转基因小鼠的衰老和前列腺增生
  • 批准号:
    6631430
  • 财政年份:
    2002
  • 资助金额:
    $ 25.29万
  • 项目类别:
Aging and Prostatic Hyperplasia in Transgenic Mice
转基因小鼠的衰老和前列腺增生
  • 批准号:
    6789388
  • 财政年份:
    2002
  • 资助金额:
    $ 25.29万
  • 项目类别:
Aging and Androgen Gene Regulation
衰老与雄激素基因调控
  • 批准号:
    7173364
  • 财政年份:
    1993
  • 资助金额:
    $ 25.29万
  • 项目类别:
Aging and Androgen Gene Regulation
衰老与雄激素基因调控
  • 批准号:
    6998439
  • 财政年份:
    1993
  • 资助金额:
    $ 25.29万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 25.29万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 25.29万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 25.29万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 25.29万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 25.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了